Tagged with R

Switzerland Daniel Weber of Boehringer Ingelheim Switzerland explores the company’s strategic initiatives and focus on innovation within the Swiss healthcare system. Weber emphasizes Boehringer Ingelheim’s long-term vision of transforming lives, its commitment to early diagnosis, and its expanding role in digital health.   Our purpose and strong pipeline are what truly…

Switzerland Incyte’s Jonathan Dickinson discusses the company’s mission to address unmet medical needs in oncology and autoimmune diseases while expanding its footprint across Europe. He highlights the strategic role of Incyte’s internal research, clinical trials, and recent product launches, along with their ambitions to double European revenues in the coming years.…

Switzerland Johnson & Johnson Innovative Medicine’s Max Pahlow discusses how the company’s commitment to innovation and patient care drives its success in Switzerland. He highlights the importance of advancing clinical trials, digitalization, and modernizing the pricing and reimbursement system to maintain Switzerland’s competitive edge in healthcare.   Switzerland isn’t a lucky…

Switzerland World-renowned oncologist Professor Susan Gasser outlines the innovative public-private partnership model in place at the ISREC Foundation at the AGORA Cancer Research Center in Lausanne. The unique model of ISREC/AGORA involves a reversal of the typical PPP structure, where the private foundation builds infrastructure and invites public institutions to collaborate,…

Global The Top 10 medical device manufacturers for 2024 ranked by sales value for the past year. As compiled by Medical Product Outsourcing, Medtronic sits at the top of this year’s list with a full USD 32.36 billion in sales, driven primarily by organic rather than acquisition-based growth. J&J Medtech is…

Mexico The lowest spender on healthcare as a percentage of GDP in mainland Latin America. A complex and fragmented reimbursement system. Clinical trial approval delays stretching across eight months. One could be forgiven for thinking that attempting to bring innovative medicines to Mexico is a thankless task. Yet, as several country…

LatAm An overview of some of the biggest news from Latin American pharma, including Onconic Therapeutics’ licensing deal with Laboratorios Sanfer for 19 LatAm countries; Lupin’s orphan drug partnership with Argentina’s Celnova Pharma; Grifols’ distribution deal with Gema Biotech; the downturn in Uruguay’s medicinal canibis industry, and Novartis’ increased clinical trial…

France At the 13th annual meeting of French life sciences think tank, G5 Santé – which represents the leaders of eight major French health and life sciences companies, including bioMérieux, Sanofi, Ipsen, and Pierre Fabre – arguments were made for increasing efficiency in a healthcare system that is “on its last…

Switzerland Dr Frank Ruhli discusses the importance of attracting top talent and fostering academic freedom as key factors in achieving research excellence. Ruhli highlights his collaborative leadership style, significant achievements like establishing the One Health Institute, the value of international partnerships in advancing interdisciplinary medical research, and some of the key…

Switzerland Dr René Buholzer, CEO of Interpharma, covers Switzerland’s healthcare advancements, regulatory progress, and the challenges in drug access and digitalization over the past three years. Emphasising collaboration and innovation, Interpharma’s ‘Pharma Strategy 2030’ aims to solidify Switzerland’s leadership in R&D and healthcare sustainability.   Our vision is not just about…

Switzerland The Federal Office of Public Health (FOPH) is the body responsible for safeguarding public health in Switzerland, developing national health policies, and overseeing the Swiss healthcare system. In an exclusive conversation, FOPH Director Anne Lévy discusses the key challenges facing the Swiss healthcare system today and highlights potential solutions as…

Switzerland Thomas Wirth shares insights into Biomed’s strategic focus on the Swiss pharmaceutical market, offering comprehensive services from regulatory support to market access for RX and OTC products. He discusses Biomed’s commitment to long-term partnerships, technological advancements, and driving operational efficiency to stay competitive.   At Biomed, we prioritize delivering value…